Abstract
Objective: The JAK1/2 inhibitor ruxolitinib has been prescribed in myelofibrosis (MF) to reduce spleen size, but has been shown to be associated with drug-induced anemia and (or) thrombocytopenia. However, data regarding the use and safety profile of this drug in the elderly are scarce. Thus, our aim was to analyze the benefits and side effects of ruxolitinib in MF patients aged Methods: Cross-sectional, retrospective study conducted in the Department of Hematology, Center of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute, a tertiary reference hospital in Bucharest, Romania. Results: A total of 50 patients with MF were enrolled in our study: 50.0% (n=25) were aged Conclusions: According to our findings, elderly patients with MF frequently required a dose reduction to tolerate ruxolitinib treatment, whereas younger patients did not. Surprisingly, despite the dose reduction, the decrease in spleen size was more important in elder patients versus younger patients with MF. However, elderly MF patients also experienced a more significant reduction of the hemoglobin value while on ruxolitinib.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
